Business Wire

Bioptimus Launches H-optimus-0, the World's Largest Open-Source AI Foundation Model for Pathology

Share

Less than five months after its launch, French startup Bioptimus has announced the release of H-optimus-0, the world’s largest open-source AI foundation model for pathology. With 1.1 billion parameters, H-optimus-0 is trained on a proprietary dataset of several hundreds of millions of images extracted from over 500,000 histopathology slides across 4,000 clinical practices. This sets a new benchmark for state-of-the-art performance in several critical medical diagnostic tasks, from identifying cancerous cells to detecting genetic abnormalities in the tumor.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240711578499/en/

Rodolphe Jenatton, CTO of Bioptimus: “Having launched less than five months ago, we are excited to introduce H-optimus-0, a fully open-source model that represents a significant leap forward in the field of pathology. We are committed to advancing medical research and improving patient care. By encouraging collaboration and the adoption of new practices, we aim to speed up innovations in pathology and beyond, ultimately benefiting patients worldwide.”

Pathology is the cornerstone of disease diagnosis, requiring meticulous examination of tissue samples to identify abnormalities. Traditionally, this process relies heavily on pathologists' expertise and experience. However, the increasing complexity and volume of cases necessitate advanced tools that can assist pathologists in making faster, more accurate diagnoses.

H-optimus-0 Key Features and Capabilities

  • Unmatched Scale and Performance: With 1.1 billion parameters, H-optimus-0 is the largest open-source AI model tailored specifically for pathology, ensuring comprehensive analysis and high accuracy.
  • Extensive Training Dataset: Trained on a vast dataset of over 500,000 pathology slides, H-optimus-0 has been exposed to a diverse array of cases, enabling it to generalize effectively across different diagnostic scenarios.
  • State-of-the-Art Diagnostics: H-optimus-0 achieves state-of-the-art performance in several key diagnostics tasks, consistently meeting the performance or outperforming existing models and setting new standards in the field. The model was assessed on 5 tile-level tasks to identify tissue types or tissue characteristics and 6 slide-level tasks to detect the presence of biomarkers or the presence of metastasis across several cancer types.
  • Open Source Availability: As an open-source model, H-optimus-0 can be utilized by researchers to accelerate the development of novel digital pathology models and will foster collaboration among researchers, clinicians, and developers, driving further advancements and solutions in pathology AI.

With its unprecedented scale and depth of training within the open-source community, H-optimus-0 leverages cutting-edge AI technology to enhance the precision and efficiency of pathology diagnostics.

Professor Jean-Philippe Vert, PhD, co-founder and CEO of Bioptimus, said: “H-optimus-0 is just the beginning. It marks the first in a long series of models we will create at Bioptimus, each more advanced and comprehensive than the last. Future models will not only be trained on an even larger number of pathology images from Europe, Asia and Africa but will also incorporate other modalities, such as genomics and proteomics. Our ultimate goal is to create the first multiscale foundation model of biology, capable of integrating diverse biological data and scales to enable scientific discoveries and accelerate biomedical innovations.”

You can access the model, detailed documentation, and research findings on our GitHub repository here.

About Bioptimus

Bioptimus is building the universal AI foundation model in biology to drive advancements in scientific research and biotechnological innovation. Leveraging a team of world-class experts, employing state-of-the-art AI technologies and accessing unique proprietary data at scale, we aim to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond. For more information, please visit https://www.bioptimus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240711578499/en/

Contacts

stephanie.libous@owkin.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Esri Press Book by Jack Dangermond Explores Creating a Better Future through Modern GIS17.7.2024 20:46:00 CEST | Press release

Esri, the global leader in location intelligence, today announced the publication next month of The Power of Where: A Geographic Approach to the World's Greatest Challenges. Written by Esri president Jack Dangermond with a dedicated Esri team and numerous contributors, this important new book explores the geographic approach—a way of solving problems using spatial analysis to perceive and understand patterns ranging from wildlife migration and rising seas to urban planning and food production. According to Dangermond, sustainability begins with geography. "I believed this when we started Esri, and I'm even more convinced today," says Dangermond. "GIS [geographic information system technology] provides a platform for addressing problems, exploring alternatives, designing solutions, and sharing them in a visual way that inspires action." The Power of Where shows through maps and stories how the growing GIS community is facing humanity's big challenges, including climate change, hunger, w

Egle Therapeutics to share preclinical data for its first autoimmune disease program, EGL-003, with an oral presentation at the 2024 Promise of Interleukin-2 Therapy Meeting17.7.2024 18:00:00 CEST | Press release

Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will deliver an oral presentation at The Promise of Interleukin-2 Therapy meeting taking place in Paris from September 4th to 7th, 2024. The presentation, entitled “EGL-003, a novel IL-2 mutein to selectively expand and activate regulatory T cells and improve therapeutic efficacy in autoimmune disease”, will show evidence that EGL-003, a non-targeted Fc-fused IL-2 agonist mutein, selectively binds to regulatory T cells (Treg) and induces Treg IL-2 signaling. The resulting increase of Treg frequencies was observed in vitro and in different mouse models. Accordingly, EGL-003 significantly improved clinical, macroscopic, and histological parameters in a DSS-induced colitis mouse model with expansion of tissue-resident Tregs. EGL-003 is the first drug candidate being developed for treatment of autoimmune diseases in Egle’s pipeline and h

Mouser Electronics Unlocks Game-Changing Human-Machine Interfaces in Latest Content Series17.7.2024 17:11:00 CEST | Press release

Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, today released the latest installment of its Empowering Innovation Together (EIT) technology series, exploring the unique attributes of human-machine interfaces (HMI) for everyday devices and industrial applications. With the evolution of HMI, engineers are blending intuitive, user-centric designs with cutting-edge technologies to introduce a host of novel capabilities. In this series, Mouser takes a deeper look at the future technological and societal impact of HMIs across our devices, cars, houses, and each other. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240717572923/en/ Enter the world of HMI and Human Factors, where engineers and researchers delve into the psychological, physiological, and ergonomic aspects of designing interfaces for human-machine interaction to optimize user experi

LambdaTest Integrates Allure Reports with HyperExecute for Enhanced Test Reporting17.7.2024 17:00:00 CEST | Press release

LambdaTest, a leading cloud-based unified testing platform, is thrilled to announce the integration of Allure Reports with HyperExecute. This new integration aims to transform the test reporting landscape, offering a more streamlined, detailed, and visually appealing way to manage and review test results. Allure Framework is a versatile, lightweight, multi-language test reporting tool that provides a concise representation of tested functionalities through visually appealing web reports. It facilitates the easy extraction of valuable information for all stakeholders involved in the development process, enhancing collaboration and efficiency. For teams already utilizing Allure reports, the integration with HyperExecute allows for the seamless generation of consolidated Allure reports for each job. These reports are accessible through the report section of the HyperExecute dashboard, centralizing test insights and simplifying management. Additionally, HyperExecute users can enhance their

LTIMindtree Delivers 2.6% QoQ USD Revenue Growth in CC17.7.2024 16:40:00 CEST | Press release

LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced its consolidated results today for the first quarter ended June 30, 2024, as approved by its Board of Directors. “While the environment remains unchanged, fiscal 25 started on a positive note for us with Q1FY25 revenue of USD 1.1 billion, registering a 2.5% QoQ and 3.5% YoY revenue growth in USD terms. Our Q1FY25 EBIT expanded to 15% and order inflow remained stable at USD 1.4 billion. Our top 3 industry verticals and our largest geography have performed well sequentially. This is attributed to a measured uptick in IT spending for critical initiatives with clients balancing innovation and fiscal prudence.” -Debashis Chatterjee, Chief Executive Officer and Managing Director Key financial highlights: Quarter ended June 30, 2024 In USD: - Revenue at $1,096.2 million (+2.5% Q-o-Q / +3.5% Y-o-Y) - Net profit at $136.1 million (+2.8% Q-o-Q / -2.9% Y-o-Y) In INR: - Revenue at Rs 91,42

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye